By Fineline Cube 
Ledeinno Medical Valley announced the completion of its Series B+ and Series B++ funding rounds totaling over 200 million RMB. The Series B+ round was funded by Shining Capital, while the Series B++ round was jointly invested by Chuangjing Capital and funds managed by CICC Capital. Genesis Partners served as the exclusive financial advisor. Proceeds will be deployed across registration, commercialization and next‑generation R&D of the company’s wireless implantable neurostimulation portfolio.
Funding Milestone
| Item | Detail |
|---|---|
| Rounds | Series B+ and Series B++ |
| Total Size | Over 200 million RMB |
| Series B+ Investor | Shining Capital |
| Series B++ Investors | Chuangjing Capital; funds managed by CICC Capital |
| Financial Advisor | Genesis Partners (exclusive) |
| Announcement Date | 17 Aug 2026 |
Use of Proceeds
- SCS Commercialization: Accelerate the registration filing and commercialization of the implantable wireless spinal cord stimulation (SCS) system.
- PNS Development: Conduct clinical research and registration translation for the implantable wireless peripheral nerve stimulation (PNS) system.
- Frontier R&D: Increase R&D and clinical translation investments in cutting‑edge products, including closed‑loop neuromodulation, brain‑computer interfaces (BCIs) and brain‑spine interfaces.
Company & Technology Profile
- Founded: 2016, focused on innovative technologies and minimally invasive surgical products in neuromodulation, closed‑loop BCIs and brain‑spine interfaces.
- Technology Platform: An innovative wireless implantable neurostimulation platform underpinning the SCS, PNS and next‑generation product pipeline.
- Mission: Provide innovative therapeutic solutions for patients with neurological functional disorders worldwide.
- Differentiation: Wireless architecture and closed‑loop capabilities position the portfolio at the frontier of next‑generation neuromodulation.
Market Impact & Outlook
- Neuromodulation Landscape: Growing clinical adoption of SCS and PNS therapies for chronic pain and neurological functional disorders is expanding the addressable market for implantable stimulators in China and globally.
- Pipeline Breadth: Progressing three parallel tracks — SCS commercialization, PNS registration, and closed‑loop BCI/brain‑spine R&D — diversifies execution risk across near‑, mid‑ and long‑term horizons.
- Investor Signal: Backing from Shining Capital, Chuangjing Capital and CICC Capital‑managed funds reflects sustained institutional confidence in China’s neurotechnology sector.
- Strategic Positioning: With over 200 million RMB secured, Leadinno is positioned to convert its wireless platform into a registered, commercialized neuromodulation portfolio.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding registration timelines, clinical research plans and commercialization expectations for Leadinno’s SCS, PNS and closed‑loop neuromodulation products. Actual results may differ due to risks including trial outcomes, regulatory review and competitive dynamics.-Fineline Info & Tech